Otsuka Seeks Re-Examination Of Abilify Patent Due To Error In Original Filing
By Marius Meland ( September 6, 2004, 12:00 AM EDT) -- Japanese drug maker Otsuka Pharmaceutical Co. has filed a request with the U.S. Patent and Trademark Office for a re-examination of the basic U.S. composition of matter patent covering Abilify (aripiprazole), an antipsychotic agent marketed for the treatment of schizophrenia in the U.S. by its partner Bristol-Myers Squibb Co....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.